Skip to main content
. 2021 Nov 16;11:751159. doi: 10.3389/fonc.2021.751159

Figure 1.

Figure 1

Kaplan-Meier estimates of time to progression for 27 eligible patients with advanced hepatocellular carcinoma who were treated with lenvatinib plus immune checkpoint inhibitors.